ELI LILLY AND COMPANY Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ELI LILLY AND COMPANY stock issued during period, value, employee stock purchase plan for fiscal 2017 was $157.30M, a 64.71% increase from fiscal 2016.
- ELI LILLY AND COMPANY stock issued during period, value, employee stock purchase plan for fiscal 2016 was $95.50M, a 106.26% increase from fiscal 2015.
- ELI LILLY AND COMPANY stock issued during period, value, employee stock purchase plan for fiscal 2015 was $46.30M, a 49.95% decline from fiscal 2014.
- ELI LILLY AND COMPANY stock issued during period, value, employee stock purchase plan for fiscal 2014 was $92.50M, a 67.88% increase from fiscal 2013.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2017-12-31 | $157.30M 10-K · filed 2018-02-20 | |
| 2016-12-31 | $95.50M 10-K · filed 2018-02-20 | |
| 2015-12-31 | $46.30M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $92.50M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $55.10M 10-K · filed 2016-02-19 | |
| 2012-12-31 | $62.40M 10-K · filed 2015-02-19 | |
| 2011-12-31 | $104.90M 10-K · filed 2014-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |